EBITDA Margin % is calculated as EBITDA divided by its Revenue. Insulet's EBITDA for the
three
months ended in Dec. 2023 was $133 Mil. Insulet's Revenue for the
three
months ended in Dec. 2023 was $510 Mil. Therefore, Insulet's EBITDA margin for the quarter that ended in Dec. 2023 was 26.15%.
Insulet EBITDA Margin % Historical Data
The historical data trend for Insulet's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Insulet's EBITDA Margin %
For the Medical Devices subindustry, Insulet's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insulet's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Insulet's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Insulet's EBITDA Margin % falls into.
Insulet EBITDA Margin % Calculation
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Insulet's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insulet (NAS:PODD) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Insulet EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of Insulet's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PODD has been successfully added to your 